Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicoflex is a topical combination ointment developed by Medimpex for the treatment of musculoskeletal conditions. It contains three active ingredients: capsaicin, ethyl nicotinate, and ethylene glycol salicylate. Capsaicin acts as a counter-irritant by depleting substance P from sensory neurons; ethyl nicotinate serves as a vasodilator to improve local blood flow and absorption; and ethylene glycol salicylate provides analgesic and anti-inflammatory effects. The product is indicated for the relief of pain associated with bruises, sprains, arthrosis, myalgia, neuralgia, and sciatica, and is frequently used by athletes for muscle warm-up. Originally authorized in Hungary in 1978, the product is currently manufactured by Egis Pharmaceuticals following its acquisition of Medimpex's pharmaceutical operations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nicoflex.